IPO
Coverage Timeline
newest firstAll Coverage
IPO$212.5M IPO
Goldman-Backed Attovia Seeks $212.5M in Biotech IPO
Attovia Therapeutics is seeking up to $212.5 million in a US IPO, offering 12.5 million shares at $15-$17 each, backed by Goldman Sachs Alternatives, Deep Track Capital, Frazier Life Sciences, and venBio.
FUNDING
Crystalys Raises $130M to Push Gout Drug Through Phase 3
FUNDING$130M Series B
Crystalys Raises $130M to Push Gout Drug Through Phase 3
Crystalys Therapeutics raised a $130 million Series B led by Frazier Life Sciences to fund global Phase 3 trials of dotinurad, an oral gout drug already approved in five Asian markets, less than a year after a $205 million Series A.